Clinical Trials Logo

Acral Melanoma clinical trials

View clinical trials related to Acral Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04331093 Not yet recruiting - Acral Melanoma Clinical Trials

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Start date: April 2020
Phase: Phase 2
Study type: Interventional

Acral melanoma is a melanoma that affects acral areas of the skin, which is the most prevalent site of melanoma in non-Caucasians.Data in this subgroup is scarce.This study is to evalueate the efficiency and safety of Neoadjuvant SHR-1210 plus apatinib in this particular group,menawhile to determine the predictive value for efficiency of several biomarkers.

NCT ID: NCT00788775 Completed - Melanoma Clinical Trials

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Start date: January 23, 2009
Phase: Phase 2
Study type: Interventional

Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to test multi-targeted kinase inhibitors with potent KIT inhibitory activity in this patient population. Imatinib and other tyrosine kinase inhibitors (TKIs) have the potential to be effective in this patient population, but patients may develop resistance to treatment. Therefore, in this study, we propose to test nilotinib in patients with metastatic mucosal, acral, or chronically sun-damaged melanoma following treatment with another TKI.